AI Article Synopsis
- Acute myeloid leukemia (AML) patients with the genetic marker t(8;21) show varying levels of interleukin 7 receptor (IL7R) expression, which can be classified into low-expressing (IL7R-L) and high-expressing (IL7R-H) groups.
- Patients in the IL7R-L group have a significantly lower relapse-free survival (RFS) rate and a higher association with KIT mutations compared to IL7R-H patients.
- A decrease in IL7R expression correlates with reduced activation and proliferation of T cells, indicating that low IL7R levels at diagnosis may serve as a prognostic factor for relapse risk in this specific AML subgroup.
Article Abstract
Background: Acute myeloid leukemia (AML) with t(8;21) needs to be further stratified. In addition to leukemia cells, immune cells in tumor microenvironment participate in tumor initiation, growth and progression. Interleukins (ILs)/interleukin receptors (ILRs) interaction plays important roles in the antitumor immune response. IL7R is reported to be relevant to prognosis in solid tumor and acute lymphoblastic leukemia. However, the prognostic significance of IL7R in t(8;21) AML remains to be clarified.
Methods: Bone marrows collected from 156 newly diagnosed t(8;21) AML patients were used for testing IL7R transcript level by TaqMan-based real-time quantitative PCR (RQ-PCR), and RNAseq were performed in 15 of them. Moreover, IL7R expression at diagnosis were measured by RQ-PCR and flow cytometry (FCM) simultaneously in other 13 t(8;21) AML patients.
Results: t(8;21) AML patients had varied IL7R transcript levels and were categorized into low-expression (IL7R-L) and high-expression (IL7R-H) groups; IL7R-L was significantly associated with a lower relapse-free survival (RFS) rate (=0.0027) and KIT mutation (=0.0010). Furthermore, IL7R-L was associated with a lower RFS rate in KIT group (=0.013) and IL7R-H/KIT patients had similar RFS to KIT patients (=0.35). GO analysis enrichment showed that down-regulated genes were predominantly involved in the regulation of T cell and leukocyte activation, proliferation and differentiation in IL7R-L group. IL7R-L had significantly lower levels of Granzymes A/B, CCR7, CD28 and CD27 than IL7R-H group (all <0.05). FCM analysis showed IL7R protein was primarily expressed in CD4 T and CD8 T cell subset. A significant association was found between the transcript level of IL7R and the percentage of CD8 T cells in nucleated cells (=0.015) but not CD4 T cells (=0.47).
Conclusion: Low IL7R transcript level of bone marrow at diagnosis predicted relapse in t(8;21) AML, which might be caused by the difference in the amount, status and function of T cells.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302488 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.909104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22).
Adv Ther
January 2008
Department of Medicine, Division of Hematology/Oncology, Chang Gung Memorial Hospital-Chiayi, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.
Article Synopsis
- * In this study of 22 patients with t(8;21)(q22;q22), factors such as higher platelet counts, lower white blood cell counts, and hematopoietic stem cell transplantation (HSCT) as postremission therapy were linked to better OS.
- * The results suggest that treatment plans for AML patients with the t(8;21) genetic change should prioritize HSCT in postremission therapy to improve patient outcomes. *
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!